IVVD
NASDAQ · Biotechnology
Invivyd Inc
$1.51
+0.08 (+5.59%)
Open$1.44
Previous Close$1.43
Day High$1.52
Day Low$1.43
52W High$3.07
52W Low$0.48
Volume—
Avg Volume1.68M
Market Cap404.41M
P/E Ratio—
EPS$-0.36
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,322.5% upside
Current
$1.51
$1.51
Target
$21.48
$21.48
$15.01
$21.48 avg
$34.49
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 83.08M | 178.19M | 160.29M |
| Net Income | -81,631,808 | 4.92M | 3.11M |
| Profit Margin | -98.3% | 2.8% | 1.9% |
| EBITDA | -85,220,608 | 6.39M | 5.91M |
| Free Cash Flow | — | 2.75M | 2.88M |
| Rev Growth | — | +11.2% | +5.5% |
| Debt/Equity | — | 0.18 | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |